Bristol-Myers Squibb's Radical Transformation

From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment from Friday's episode, health-care analyst David Williamson examines what seems on the surface like a radical shift for Bristol-Myers Squibb (NYSE: BMY  ) . The company has announced that it will discontinue drug discovery in the hepatitis-C, diabetes, and neurological disorder spaces. It will instead focus on a number of treatment areas, singling out immuno-oncology as the most important for the pharma's future.

David takes a close look at this major shift and the reasons behind it, analyzes the space that Bristol-Myers is focusing on going forward, and tells investors whether this move is really as radical as it seems.

Looking for biotech profits?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2724131, ~/Articles/ArticleHandler.aspx, 8/30/2014 10:16:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement